{"id":"W2890449437","doi":"10.1200/jco.2017.35.15_suppl.tps5607","title":"FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Topotecan; Oncology; Clinical endpoint; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Carboplatin; Interim analysis; Clinical trial; Adverse effect; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002687211,0.002734547,0.003218543,0.0006986727,0.0005965613,0.001035722,0.001367478,0.002891254,0.01206311],"category_scores_gemma":[0.001956594,0.0009985355,0.002308434,0.0004922553,0.001643873,0.001409152,0.0006082142,0.004496809,0.002044175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001400899,"about_ca_system_score_gemma":0.002801402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00131814,"about_ca_topic_score_gemma":0.003894173,"domain_scores_codex":[0.999275,0.0003951161,0.00002310046,0.000121592,0.00005352927,0.0001316398],"domain_scores_gemma":[0.9984303,0.0003504921,0.0003534035,0.0001052901,0.00009846321,0.0006620195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9559646,0.01869148,0.0007066979,0.0004728009,0.0004172414,0.00008448095,0.00006872642,0.0005404313,0.004920128,0.0001947287,0.003114535,0.01482428],"study_design_scores_gemma":[0.870212,0.1269662,0.0009797977,0.00002282944,0.0001405443,0.00005060352,0.00001417142,0.0002905651,0.0003033191,0.0001650012,0.0008410455,0.00001391862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494293,0.003428915,0.001335858,0.00239494,0.0009414555,0.03010272,0.006158025,0.0004743503,0.005734422],"genre_scores_gemma":[0.9167908,0.003388323,0.006609916,0.00724803,0.000953983,0.04282562,0.008290704,0.0001488001,0.01374392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01206311,"threshold_uncertainty_score":0.04035515,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05741997394984657,"score_gpt":0.4416706588072608,"score_spread":0.3842506848574142,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}